#Germany #Frankfurt #CPHI Frankfurt #Taiwan TCM Pavilion #evidence-based TCM

Taiwan's Traditional Chinese Medicine Pavilion at CPHI Frankfurt 2025

The Taiwan Traditional Chinese Medicine (TCM) Pavilion made a remarkable entrance at CPHI Frankfurt 2025, held from October 28 to 30. This event attracted significant attention from pharmaceutical professionals and distributors globally, highlighting Taiwan's commitment to evidence-based herbal innovations. The pavilion serves as a platform for fostering partnerships and collaborations that reinforce Taiwan's reputation in the realm of traditional medicine.

A Strategic Presentation on Global Stage

Opening with an enthusiastic reception, the Taiwan TCM Pavilion was featured on the CPHI Newsbeat Stage, marking its strategy to engage with the international press directly. During this pitching session, representatives from the Taiwan Institute of Economic Research (TIER) introduced Taiwan's distinctive TCM model that intertwines traditional practices with modern scientific validation. Notably, TIER presented notable developments like NRICM101, which emerged during the COVID-19 pandemic. This formulation, backed by peer-reviewed studies, demonstrates promising efficacy in reducing severe health outcomes associated with the disease. The presentation secured interest from various media outlets including the prominent life sciences podcast, 'Molecule to Market', hosted by Raman Sehgal.

Showcasing Leading Enterprises and Innovations

The Taiwan Pavilion featured five prominent companies, namely Chuang Song Zong, Li Kang Biotech, Timing Pharmaceutical, Taiwan Three Mast, and Grape King Bio. Each of these enterprises exemplifies Taiwan's vibrant TCM industry, characterized by innovative product development and a strong dedication to research excellence. A significant highlight of the pavilion was the showcasing of NRICM101 and its counterpart, NRICM102. These formulations demonstrate multifunctional pharmacological effects that inhibit viral activities and mitigate inflammation, showcasing their role in improving health outcomes among users.

The results from NRICM102 have particularly stood out, indicating a remarkable 74% reduction in mortality rates among its users. These outcomes not only highlight the scientific merit of Taiwan's TCM advancements but also open doors for global applications in integrative healthcare.

A Message of Global Outreach

“Our fusion of traditional Chinese medicine with contemporary scientific methods is gaining worldwide recognition,” stated Dr. Yi-Chang Su, the director of the Department of Chinese Medicine and Pharmacy (DCMP) at Taiwan’s Ministry of Health and Welfare. He emphasized Taiwan's commitment to widening the reach of trusted TCM products into larger markets around the globe.

Throughout the event, representatives from the Taiwan Pavilion engaged with various stakeholders, including pharmaceutical companies, regulatory experts, and promotion organizations from Europe and the Americas, fostering discussions on potential collaboration opportunities. This collective effort aims to advance global health through Taiwan's validated TCM frameworks.

Conclusion

As the CPHI Frankfurt 2025 unfolds, Taiwan’s TCM Pavilion stands as a testament to the efficacy and global appeal of integrative medicine. With ongoing efforts to build international partnerships, Taiwan is poised to elevate its TCM practice and innovations onto the world stage, showcasing the immense potential that traditional healthcare, backed by scientific research, can offer to global health solutions.